靶向脂肪肉瘤：揭示分子途径与治疗机遇
Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.
作者信息
Liu Hongliang, Wang Xi, Liu Lingyan, Yan Bingsong, Qiu Fabo, Zhou Bin
机构信息
Department of Hepatobiliary and Pancreatic Surgery & Retroperitoneal Tumor Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Oncology, Women and Children's Hospital Affiliated to Qingdao University, Qingdao, China.
出版信息
Front Oncol. 2024 Dec 11;14:1484027. doi: 10.3389/fonc.2024.1484027. eCollection 2024.
Abstract
In recent years, an increasing number of studies have utilized molecular biology techniques to reveal important molecular heterogeneity among different subtypes of liposarcoma. Each subtype exhibits distinct genetic patterns and molecular pathways, which may serve as important targets for molecular therapy. In the present review, we focus on the molecular characteristics, molecular diagnostics, driver genes, and molecular mechanisms of liposarcoma. We also discuss the clinical research progress of related targeted therapies, with an aim to provide a reference and crucial insights for colleagues in the field.
摘要
近年来，越来越多的研究利用分子生物学技术揭示不同亚型脂肪肉瘤之间重要的分子异质性。每个亚型都表现出独特的遗传模式和分子途径，这可能成为分子治疗的重要靶点。在本综述中，我们重点关注脂肪肉瘤的分子特征、分子诊断、驱动基因和分子机制。我们还讨论了相关靶向治疗的临床研究进展，旨在为该领域的同行提供参考和重要见解。
相似文献
1
Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.靶向脂肪肉瘤：揭示分子途径与治疗机遇
Front Oncol. 2024 Dec 11;14:1484027. doi: 10.3389/fonc.2024.1484027. eCollection 2024.
2
Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.用于靶向治疗选择的脂肪肉瘤中的遗传、表观遗传和转录组改变
Cancers (Basel). 2024 Jan 8;16(2):271. doi: 10.3390/cancers16020271.
3
An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.脂肪肉瘤亚型概述：遗传改变和治疗策略的最新进展。
J Mol Histol. 2024 Jun;55(3):227-240. doi: 10.1007/s10735-024-10195-4. Epub 2024 May 2.
4
Application of molecular biology to individualize therapy for patients with liposarcoma.分子生物学在脂肪肉瘤患者个体化治疗中的应用。
Am Soc Clin Oncol Educ Book. 2015:213-8. doi: 10.14694/EdBook_AM.2015.35.213.
5
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.脂肪肉瘤的基因表达谱分析确定了高分化和去分化脂肪肉瘤中不同的生物学类型/亚型以及潜在的治疗靶点。
Cancer Res. 2007 Jul 15;67(14):6626-36. doi: 10.1158/0008-5472.CAN-07-0584.
6
Deciphering the roles of non-coding RNAs in liposarcoma development: Challenges and opportunities for translational therapeutic advances.解读非编码RNA在脂肪肉瘤发生发展中的作用：转化治疗进展面临的挑战与机遇
Noncoding RNA Res. 2024 Nov 15;11:73-90. doi: 10.1016/j.ncrna.2024.11.005. eCollection 2025 Apr.
7
Clinical and Molecular Spectrum of Liposarcoma.脂肪肉瘤的临床与分子谱。
J Clin Oncol. 2018 Jan 10;36(2):151-159. doi: 10.1200/JCO.2017.74.9598. Epub 2017 Dec 8.
8
Pharmacological therapies for Liposarcoma.脂肪肉瘤的药物治疗
Expert Rev Clin Pharmacol. 2017 Apr;10(4):361-377. doi: 10.1080/17512433.2017.1289086. Epub 2017 Feb 13.
9
Histology driven systemic therapy of liposarcoma-ready for prime time?组织学驱动的脂肪肉瘤全身治疗——已准备好进入黄金时代？
Transl Gastroenterol Hepatol. 2018 Nov 23;3:96. doi: 10.21037/tgh.2018.11.01. eCollection 2018.
10
Recent advances in the understanding and management of liposarcoma.脂肪肉瘤认识与治疗的最新进展
Fac Rev. 2021 Jan 4;10:1. doi: 10.12703/r/10-1. eCollection 2021.
引用本文的文献
1
Histomorphological and molecular characteristics of liposarcoma (Review).脂肪肉瘤的组织形态学和分子特征（综述）
Oncol Lett. 2025 Jul 21;30(4):454. doi: 10.3892/ol.2025.15200. eCollection 2025 Oct.
本文引用的文献
1
The Notch-PDGFRβ axis suppresses brown adipocyte progenitor differentiation in early post-natal mice.Notch-PDGFRβ 轴抑制新生后小鼠早期棕色脂肪祖细胞的分化。
Dev Cell. 2024 May 20;59(10):1233-1251.e5. doi: 10.1016/j.devcel.2024.03.012. Epub 2024 Apr 2.
2
Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma.蛋白质组学特征分析可识别软组织肉瘤具有临床意义的亚群。
Nat Commun. 2024 Feb 15;15(1):1381. doi: 10.1038/s41467-024-45306-y.
3
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.安罗替尼作为一线化疗后晚期软组织肉瘤的维持治疗（ALTER-S006）：一项多中心、开放标签、单臂、2期试验。
EClinicalMedicine. 2023 Sep 21;64:102240. doi: 10.1016/j.eclinm.2023.102240. eCollection 2023 Oct.
4
Bioinformatics Screen Reveals Gli-Mediated Hedgehog Signaling as an Associated Pathway to Poor Immune Infiltration of Dedifferentiated Liposarcoma.生物信息学筛选揭示Gli介导的Hedgehog信号通路是去分化脂肪肉瘤免疫浸润不良的相关通路。
Cancers (Basel). 2023 Jun 27;15(13):3360. doi: 10.3390/cancers15133360.
5
The proteomic landscape of soft tissue sarcomas.软组织肉瘤的蛋白质组学全景。
Nat Commun. 2023 Jun 29;14(1):3834. doi: 10.1038/s41467-023-39486-2.
6
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.MDM2-p53 拮抗剂 Brigimadlin（BI 907828）治疗晚期或转移性实体瘤患者的Ⅰa 期、首次人体、剂量递增研究结果。
Cancer Discov. 2023 Aug 4;13(8):1802-1813. doi: 10.1158/2159-8290.CD-23-0153.
7
Transcriptome analysis identifies TODL as a novel lncRNA associated with proliferation, differentiation, and tumorigenesis in liposarcoma through FOXM1.转录组分析鉴定 TODL 为一种新型 lncRNA，通过 FOXM1 与脂肪肉瘤的增殖、分化和肿瘤发生相关。
Pharmacol Res. 2022 Nov;185:106462. doi: 10.1016/j.phrs.2022.106462. Epub 2022 Sep 24.
8
Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers.除了在高分化和去分化脂肪肉瘤中靶向扩增的MDM2和CDK4：从前景与临床应用到鉴定进展驱动因素。
Front Oncol. 2022 Sep 2;12:965261. doi: 10.3389/fonc.2022.965261. eCollection 2022.
9
Review: Precise sarcoma patient-derived orthotopic xenograft (PDOX) mouse models enable identification of novel effective combination therapies with the cyclin-dependent kinase inhibitor palbociclib: A strategy for clinical application.综述：精确的肉瘤患者来源原位异种移植（PDOX）小鼠模型有助于确定细胞周期蛋白依赖性激酶抑制剂帕博西尼的新型有效联合疗法：一种临床应用策略。
Front Oncol. 2022 Aug 8;12:957844. doi: 10.3389/fonc.2022.957844. eCollection 2022.
10
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.一项在晚期尤文肉瘤和相关软组织及骨源性肿瘤患者中应用regorafenib 的 II 期临床试验：SARC024 试验结果。
Cancer Med. 2023 Jan;12(2):1532-1539. doi: 10.1002/cam4.5044. Epub 2022 Aug 10.
Zotero 插件